Corporate vision
To make the world easy for all to see
Precision Sight (Beijing) Medical Technology Co., Ltd. is a new medical technology company driven by artificial intelligence with the goal of providing quality vision rehabilitation products. The optometric products of Precision Sight make full use of the technical achievements of combining brain vision science and computer vision, and are dedicated to the improvement, recovery and enhancement of human visual perception function, so that everyone can easily see the world and no longer suffer from visual impairment through the means of technology.
U-Vision Visual Function Therapy Program
Asynchronous dichoptic visual stimulation Ι New animated video training format Ι At-home training mode
Our Strengths
Provide professional visual rehabilitation services for patients with visual impairment through advanced and precise diagnosis and treatment technology
Product
The company has formed an optometric product line focusing on the detection, prevention, control and treatment of pediatric amblyopia, myopia and glaucoma. Among them, the pediatric amblyopia digital therapy products have obtained the registration certificate and manufacturing license of Class II medical devices.
Technology
The company's vision rehabilitation platform is based on the latest research results in international brain vision neuroscience, using virtual reality technology for visual training therapy combined with big data models for personalized treatment plans to provide patients with accurate treatment products.
Patents
The core technology of amblyopia treatment has been authorized by five national invention patents, and one U.S. patent and one European Patent Office patent have been submitted for application.
Research
Relying on the research of Key Laboratory of Visual Impairment and Repair of Ministry of Education, School of Basic Medical Sciences, Peking University for many years. He has published many academic papers on neural mechanisms of retinal diseases and visual function repair in international professional academic journals. His research on amblyopia treatment products has been funded by two national 973 projects.
Clinical
The company has maintained close cooperation with many research and medical institutions. Clinical trials for amblyopia treatment have been conducted in several hospitals.
Team
The company was founded in April 2018 by a scientific and technical team led by Professor Mingliang Pu from the Visual Function Reconstruction Laboratory of Peking University, with an interdisciplinary product development team integrating neuroscience, optometric science and artificial intelligence technology and a marketing and sales team that closely follows customer needs.
Clinical Partners
The company maintains close cooperation with several clinical trial institutions
